| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 1289-1297, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
SA Vinores, M Kuchle, J Mahlow, C Chiu, WR Green and PA Campochiaro
Wilmer Ophthalmologic Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9289, USA.
A series of 130 eyes with ocular melanomas, 19 normal eyes, and 18 eyes affected with other disorders leading to blood-ocular barrier (BOB) breakdown were immunohistochemically stained for albumin to localize sites of BOB failure within the retina, ciliary body, and iris. Thirty- nine of the eyes containing melanomas and all of the other eyes were also immunohistochemically stained for vascular endothelial growth factor (VEGF), to investigate its potential role as a mediator for BOB failure. Eyes with melanomas showed widespread leakage through the retinal pigment epithelium, and 58% demonstrated leakage from retinal vessels in the proximity of the tumor. BOB failure remote from the tumor also occurred in retina (50%), optic nerve head (77%), ciliary body (51%), and iris (51%), suggesting that a soluble mediator may be involved. VEGF was demonstrated intraretinally in the proximity of (46%) and remote from (24%) melanomas and in eyes affected by other disease processes, particularly those involving neoplasia or retinal detachments, usually within particular cell populations (ie, retinal vessel walls, ganglion cells, inner or outer nuclear layers, retinal pigment epithelium). VEGF localization in retina, ciliary body, and iris often coincided with sites of extravasated albumin. Preincubation of albumin or VEGF antibodies with normal serum or VEGF peptide, respectively, eliminated or markedly reduced all immunoreactivity. Only 1 of 14 normal postmortem eyes and 0 of 5 normal surgically removed eyes showed VEGF positivity in the retina, 5 of 19 normal eyes had weak positivity in the ciliary body, and VEGF was not demonstrated in the iris of normal eyes. VEGF cannot account for all of the BOB failure associated with ocular melanomas, but appears likely to play a contributing role in many cases.
This article has been cited by other articles:
 |
|
 |
|
  G. S. O. Missotten, I. C. Notting, R. O. Schlingemann, H. J. Zijlmans, C. Lau, P. H. C. Eilers, J. E. E. Keunen, and M. J. Jager Vascular Endothelial Growth Factor A in Eyes With Uveal Melanoma Arch Ophthalmol, October 1, 2006; 124(10): 1428 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Lee, K. H. Baratz, J. S. Pulido, and D. R. Salomao Expression of vascular endothelial growth factor in iris melanoma. Arch Ophthalmol, September 1, 2006; 124(9): 1349 - 1350. [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Witmer, B. C. van Blijswijk, C. J.F. van Noorden, G. F.J.M. Vrensen, and R. O. Schlingemann In Vivo Angiogenic Phenotype of Endothelial Cells and Pericytes Induced by Vascular Endothelial Growth Factor-A J. Histochem. Cytochem., January 1, 2004; 52(1): 39 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G. O. H. Naumann Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4473 - 4480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Patel, L. Sun, D. Moshinsky, H. Chen, K. M. Leahy, P. Le, K. G. Moss, X. Wang, A. Rice, D. Tam, et al. A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Feeney, D. A. C. Simpson, T. A. Gardiner, C. Boyle, P. Jamison, and A. W. Stitt Role of Vascular Endothelial Growth Factor and Placental Growth Factors During Retinal Vascular Development and Hyaloid Regression Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 839 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Walker, P. R. van Ginkel, R. L. Gee, H. Ahmadi, L. Subramanian, B. R. Ksander, L. F. Meisner, D. M. Albert, and A. S. Polans Expression of Angiogenic Factors Cyr61 and Tissue Factor in Uveal Melanoma Arch Ophthalmol, December 1, 2002; 120(12): 1719 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Derevjanik, S. A. Vinores, W.-H. Xiao, K. Mori, T. Turon, T. Hudish, S. Dong, and P. A. Campochiaro Quantitative Assessment of the Integrity of the Blood-Retinal Barrier in Mice Invest. Ophthalmol. Vis. Sci., July 1, 2002; 43(7): 2462 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Boyd, D S W Tan, L de Souza, M H Neale, N E Myatt, R A Alexander, M Robb, J L Hungerford, and I A Cree Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth Br. J. Ophthalmol., April 1, 2002; 86(4): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S R Boyd, D Tan, C Bunce, A Gittos, M H Neale, J L Hungerford, S Charnock-Jones, and I A Cree Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window Br. J. Ophthalmol., April 1, 2002; 86(4): 448 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P H M Muskens, J A Van Best, J C Bleeker, and J E E Keunen Corneal autofluorescence in choroidal melanoma or in choroidal naevus Br. J. Ophthalmol., June 1, 2001; 85(6): 662 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G Sheidow, P. L Hooper, C. Crukley, J. Young, and J G. Heathcote Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis Br. J. Ophthalmol., July 1, 2000; 84(7): 750 - 756. [Abstract] [Full Text]
|
|
|
|
|
|
D. KENT, S. A VINORES, and P. A CAMPOCHIARO Macular oedema: the role of soluble mediators Br. J. Ophthalmol., May 1, 2000; 84(5): 542 - 545. [Full Text]
|
|
|
|
 |
|
 M. Inoue, H. Itoh, M. Ueda, T. Naruko, A. Kojima, R. Komatsu, K. Doi, Y. Ogawa, N. Tamura, K. Takaya, et al. Vascular Endothelial Growth Factor (VEGF) Expression in Human Coronary Atherosclerotic Lesions : Possible Pathophysiological Significance of VEGF in Progression of Atherosclerosis Circulation, November 17, 1998; 98(20): 2108 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hata, E. Duh, K. Zhang, G. S. Robinson, and L. P. Aiello Transcription Factors Sp1 and Sp3 Alter Vascular Endothelial Growth Factor Receptor Expression through a Novel Recognition Sequence J. Biol. Chem., July 24, 1998; 273(30): 19294 - 19303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-S. Chen, S. F Hackett, C.-L. Schoenfeld, M. A Vinores, S. A Vinores, and P. A Campochiaro Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes Br. J. Ophthalmol., October 1, 1997; 81(10): 919 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br. J. Ophthalmol., June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
|
|
|
|
|
M. Kliffen, H. S Sharma, C. M Mooy, S. Kerkvliet, and P. T V M de Jong Increased expression of angiogenic growth factors in age-related maculopathy Br. J. Ophthalmol., February 1, 1997; 81(2): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
